---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-170509"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:55:01.756237+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Definium provides DT120 ODT clinical updates; MDD/GAD readouts in 2H 2026, expansion into PTSD

## Summary
- MDD Emerge trial topline data on track for late 2Q 2026; 149 participants randomized 1:1 to DT120 100 µg or placebo.
- GAD Voyage trial fully enrolled at 214 participants; topline data expected early 3Q 2026.
- GAD Panorama sample size re-estimated to 200; screening closed, topline readout now late 3Q 2026 (previously 2H 2026).
- PTSD program expanded with Phase 3 Haven study (~200 pts) initiating in 2027; primary endpoint CAPS-5 at Week 8.
- Company presented commercial strategy for DT120 ODT as a potential multi-billion-dollar opportunity.

## SEC filing metadata
- accession: 0001193125-26-170509
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000119312526170509/0001193125-26-170509-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000119312526170509/dftx-20260422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-170509
- JSON: https://secwatch.observer/filing/0001193125-26-170509.json
- Plain text: https://secwatch.observer/filing/0001193125-26-170509.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.